# 深脑刺激器市场

> 深脑刺激器（DBS）市场研究报告按设备类型（单导线DBS、双导线DBS、自适应DBS）、应用领域（帕金森病、特发性震颤、肌张力障碍、强迫症）、植入技术（立体定向手术、微电极记录、神经影像引导）、最终用户（医院、神经科诊所、研究机构）、技术（传统DBS系统、闭环DBS系统、无线DBS系统）以及按地区（北美、欧洲、南美、亚太、中东和非洲）- 预测到2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.89%
- **2024:** $ 5.36 Billion
- **2025:** $ 5.67 Billion
- **2035:** $ 10.05 Billion
- **Key Players:** Medtronic (US), Boston Scientific (US), Abbott (US), NeuroPace (US), St. Jude Medical (US), Stryker (US), Zynex (US), Bioness (US)

**Report ID:** MRFR/HC/30550-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** September 17, 2026

**URL:** https://www.marketresearchfuture.com/reports/deep-brain-stimulators-market-32343

---

## Market Summary

## **Deep Brain Stimulators DBS Market Overview**

As per MRFR analysis, the Deep Brain Stimulators Market Size was estimated at 5.36 (USD Billion) in 2024. The Deep Brain Stimulators Market Industry is expected to grow from 5.67 (USD Billion) in 2025 to 9.49 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 5.89% during the forecast period (2025 - 2034).

### **Key Deep Brain Stimulators DBS Market Trends Highlighted**

The global deep brain stimulators (DBS) market is being largely driven by the increasing prevalence of neurological disorders such as** Parkinson’s disease, essential tremors**, dystonia, and epilepsy. As the aging population continues to grow, the demand for innovative treatment modalities that can improve quality of life has intensified. Additionally, advancements in neurotechnology, including miniaturization of devices and enhanced battery life, are fueling the development of more effective and patient-friendly DBS systems.

As healthcare professionals become more aware of the efficacy of DBS, a shift towards early intervention and personalized medicine is emerging, further solidifying its relevance in treating complex neurological conditions. Opportunities in the global DBS market remain ripe for exploration, particularly in emerging economies where healthcare infrastructure is gradually improving. There is significant potential for expansion in regions with limited access to advanced neuromodulation therapies, as increased awareness can lead to greater uptake.

The integration ofartificial intelligence and machine learning into DBS systems is another avenue that presents new possibilities, enhancing patient outcomes through tailored stimulation protocols. Furthermore, the growing trend of home healthcare emphasizes the need for portable and user-friendly devices that can facilitate remote monitoring and adjustments. In recent times, the market has witnessed a notable trend towards the development of closed-loop DBS systems that adapt stimulation in real-time based on neural feedback.

This innovation not only aims to optimize therapeutic outcomes but also to increase patient compliance by minimizing side effects. Another relevant trend is the consolidation of key players in the market as companies strive to innovate and expand their product portfolios. Overall, the global deep brain stimulators market is on a path of dynamic growth, shaped by technological advancements, evolving patient needs, and an enhanced focus on individualized care.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Deep Brain Stimulators DBS Market Drivers**

### **Increasing Prevalence of Neurological Disorders**

The Global Deep Brain Stimulators DBS Market Industry is significantly driven by the rising prevalence of neurological disorders such as Parkinson's disease, essential tremor, and dystonia. As the global population ages, the occurrence of these conditions has been steadily increasing, leading to a higher demand for innovative treatment options. Deep Brain Stimulation (DBS) has emerged as a favored therapeutic option due to its ability to reduce symptoms, enhance quality of life, and allow patients to respond better to medication.

This growing patient population has necessitated advancements in DBS technology, encouraging companies to research and develop new devices and solutions. Furthermore, as awareness regarding the benefits of DBS therapy spreads, we expect an upward trend in product adoption, contributing positively to market growth. Increased investments in healthcare infrastructures and rising healthcare expenditure further augment the market, catering to the heightened need for effective neurological treatments.

In summary, the growing incidence of neurological conditions serves as a pivotal driver for the Global Deep Brain Stimulators DBS Market Industry as it fuels the demand for DBS devices and the development of innovative therapies.

### **Technological Advancements in Deep Brain Stimulation Devices**

The Global Deep Brain Stimulators DBS Market Industry is witnessing rapid technological advancements that are enhancing the effectiveness and usability of DBS devices. Innovations such as closed-loop systems, brain-computer interfaces, and advanced neuroimaging techniques are improving targeting precision, reducing side effects, and optimizing therapeutic outcomes. These developments facilitate more personalized treatments, catering to individual patient needs and enhancing device functionality.

As technology progresses, new entrants, along with existing players, are increasingly focusing on R&D activities to innovate and refine the current offerings, thus driving market growth.

### **Growing Investment in Neurostimulation Research**

The Global Deep Brain Stimulators DBS Market Industry is experiencing considerable growth due to the rising investment in neurostimulation research. Various stakeholders, including governments, academic institutions, and private organizations, are increasingly allocating resources toward understanding the brain and developing advanced neurostimulation techniques. Such investments have been instrumental in propelling breakthrough research and translating these findings into practical applications.

Financial support for clinical trials and innovative projects boosts the development of new DBS devices and technologies, enhancing the overall market landscape and fostering competitive dynamics.

## **Deep Brain Stimulators DBS Market Segment Insights**

### **Deep Brain Stimulators DBS Market Device Type Insights**

The Global Deep Brain Stimulators DBS Market revenue showcases significant growth driven by advancements in technology and increasing neurological disorders, with the device type segment playing a crucial role in shaping market dynamics. Among the various types of devices, Single Lead DBS has emerged as a dominant force, capturing a substantial market valuation of 2.57 USD Billion in 2023 and projected to reach 4.3 USD Billion by 2032.

This growth can be attributed to its effectiveness in treating movement disorders such as Parkinson’s disease, where it offers targeted stimulation with less complexity. Similarly, the Dual Lead DBS segment also displays a noteworthy presence, valued at 1.56 USD Billion in 2023 and expected to grow to 2.55 USD Billion by 2032. This dual-lead configuration provides enhanced therapeutic benefits by stimulating different brain regions simultaneously, making it a preferred option for complex neurological cases.

Adaptive DBS, although comparatively smaller, is valued at 0.65 USD Billion in 2023 and is anticipated to increase to 1.15 USD Billion by 2032. Its real-time adjustments to patient needs position it as a significant innovation in the market, particularly for patients requiring personalized treatment regimens. The growth in these device types is driven by favorable trends such as increasing awareness of DBS technology, an aging population, and rising healthcare expenditure.

However, challenges such as high treatment costs and procedural risks could impede growth. The Global Deep Brain Stimulators DBS Market statistics reflect a promising outlook as technological advancements lead to more efficient devices, ensuring better patient outcomes and broader adoption across the healthcare landscape. As demand continues to grow, opportunities will likely arise for new entrants focused on advancing DBS technologies, thus enhancing the overall market potential.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

### **Deep Brain Stimulators DBS Market Application Area Insights**

The Global Deep Brain Stimulators DBS Market is experiencing consistent growth, particularly within the Application Area segment, where in 2023, the market was valued at approximately 4.78 USD Billion. This growth is driven by an increase in neurodegenerative diseases and mental health disorders requiring innovative treatment solutions. Among the various applications, Parkinson’s Disease plays a substantial role, as it represents a significant part of the market due to the rising prevalence of this condition and the effectiveness of DBS as a therapeutic option.

Essential Tremor also holds importance, impacting patients’ quality of life and presenting an opportunity for market expansion. Similarly, Dystonia is a notable area driving demand for DBS, given its complex nature and the challenges it presents ineffective management. Additionally, Obsessive-Compulsive Disorder showcases the versatility of deep brain stimulation in addressing mental health issues, bringing heightened attention to this field. The evolving landscape is characterized by advancements in technology and increasing awareness, which collectively contribute to the market growth and dynamics represented in Global Deep Brain Stimulators DBS Market statistics and data.

### **Deep Brain Stimulators DBS Market Implantation Technique Insights**

The Global Deep Brain Stimulators DBS Market is poised for growth, with substantial value attributed to various Implantation Techniques. In 2023, the overall market was valued at 4.78 billion USD, reflecting the increasing adoption of DBS for neurological disorders. The Implantation Technique segment includes vital methodologies like [Stereotactic Surgery](../../../reports/stereotactic-surgery-devices-market-6791), Microelectrode Recording, and Neuroimaging Guided approaches. Stereotactic Surgery has become crucial for precise targeting during device placement, enhancing treatment efficacy.

Microelectrode Recording is significant for real-time neural activity monitoring, contributing to personalized treatment. Neuroimaging-guided techniques enable accurate planning and execution of surgeries, ensuring optimal outcomes. The insights into these methodologies reveal a trend towards precision medicine, driven by advancements in technology and growing patient demand for effective and minimally invasive treatments.

This segment not only represents the backbone of the overall DBS market but also showcases the industry's commitment to improving patient quality of life through innovative implantation approaches. As the market continues to expand, understanding these techniques will be essential in navigating market dynamics and opportunities.

### **Deep Brain Stimulators DBS Market End User Insights**

The Global Deep Brain Stimulators DBS Market is poised for robust growth as it addresses essential healthcare needs across various segments, particularly within hospitals, neurology clinics, and research institutes. As of 2023, the market showed a valuation of 4.78 billion USD, reflecting the escalating demand for treatment options for neurological disorders. Hospitals represent a significant portion of the market, given their comprehensive services and advanced facilities, making them crucial for patient management and post-procedure care.

Neurology clinics also play a pivotal role as specialized centers, offering tailored treatments and attracting patients seeking focused neurological care. Meanwhile, research institutes contribute to the market by driving innovation and development of new technologies and therapies, ensuring sustained growth and evolution in deep brain stimulation methods. Overall, factors such as rising incidences of neurological disorders, enhanced healthcare infrastructure, and increasing awareness about treatment options are propelling the market forward. The Global Deep Brain Stimulators DBS Market data further illustrates that these key end-user segments are instrumental in shaping the industry's landscape, presenting both challenges and opportunities as the market continues to expand.

### **Deep Brain Stimulators DBS Market Technology Insights**

The Global Deep Brain Stimulators DBS Market, valued at 4.78 USD Billion in 2023, showcases a diverse Technology segment that significantly accounts for market growth. This encompasses Conventional DBS Systems, Closed-Loop DBS Systems, and Wireless DBS Systems, each offering unique advantages for patients suffering from neurological disorders. Conventional DBS Systems remain widely utilized due to their established efficacy and reliability addressing symptoms in conditions like Parkinson’s disease.

Closed-loop DBS Systems are gaining momentum, providing adaptive stimulation based on real-time neural feedback, which enhances treatment effectiveness and optimizes resource utilization. Wireless DBS Systems have emerged as a significant player in the market, enabling easier monitoring and patient compliance through remote access to data, which is deemed beneficial in today’s tech-centric healthcare environment. The dynamic shift towards advanced technologies fosters an environment ripe with opportunities while simultaneously presenting challenges such as compatibility and regulatory hurdles.

As the market continues to evolve with innovations, the emphasis on tailored therapeutic approaches through these technologies fuels substantial growth prospects within the overall Global Deep Brain Stimulators DBS Market industry.

### **Deep Brain Stimulators DBS Market Regional Insights**

The Global Deep Brain Stimulators DBS Market is poised for significant growth across various regional markets, showcasing diverse dynamics and potential. In 2023, North America leads with a substantial market valuation of 2.1 USD Billion, primarily driven by advanced healthcare infrastructure and a high prevalence of neurological disorders, establishing it as a dominant force. Europe follows closely with a valuation of 1.5 USD Billion, reflecting growing investment in healthcare innovation and increasing adoption of DBS technology.

The Asia Pacific region, valued at 0.9 USD Billion, presents significant opportunities due to rising awareness and improvements in healthcare facilities, indicating a promising trajectory for market expansion. Meanwhile, South America and the Middle East and Africa hold smaller market shares at 0.18 USD Billion and 0.1 USD Billion, respectively, in 2023, yet are gradually seeing growth driven by increasing healthcare access and neurological health awareness. The revenue distribution indicates a significant majority holding in North America and Europe, highlighting their pivotal role in the Global Deep Brain Stimulators DBS Market industry, while the Asia Pacific region's growth potential reflects evolving healthcare needs and market demand.

**Source: Primary Research, Secondary Research, MRFR Database and Analyst Review**

## **Deep Brain Stimulators DBS Market Key Players And Competitive Insights**

The Global Deep Brain Stimulators (DBS) Market has witnessed significant growth, spurred by advancements in the technology of neurological treatments and the rising prevalence of movement disorders. Competitive dynamics in this market are shaped by a combination of innovation, regulatory developments, and strategic collaborations among key players. Companies are focusing on enhancing their product lines with cutting-edge features and improved safety profiles.

The market landscape is characterized by an increasing emphasis on patient-centered care, resulting in the development of DBS devices that prioritize ease of use and patient comfort. As new entrants continue to emerge, established companies are leveraging their extensive experience and clinical data to maintain their market positions while expanding their global reach.

St. Jude Medical has carved out a notable presence in the Global Deep Brain Stimulators DBS Market through its strong portfolio of innovative products designed for the treatment of neurological diseases. The company is recognized for its commitment to research and development, allowing it to stay ahead of the competition by offering advanced stimulation technologies that improve patient outcomes. With a focus on user-friendly designs and customizable therapies, St. Jude Medical has garnered the trust of healthcare professionals and patients alike.

The company's strategic partnerships and collaborations enhance its market leverage, while its robust supply chain and strong customer relationships indicate a competitive strength in addressing the needs of various markets globally. The emphasis on clinical evidence to support its products further enriches St. Jude Medical's reputation as a reliable provider in the DBS arena. Medtronic has established itself as a formidable competitor in the Global Deep Brain Stimulators DBS Market through its dedication to innovation and comprehensive approach to neurological therapies.

The company is renowned for its pioneering work in developing advanced DBS systems that offer flexible programming options and precise targeting features, tailoring treatments to individual patient needs.

Medtronic's extensive experience in the medical device sector bolsters its credibility and market presence, as its products are backed by extensive clinical validation and safety data. The strong global distribution network enables Medtronic to reach diverse patient populations effectively. Additionally, Medtronic’s commitment to integrating advanced technologies, such as software advancements and remote monitoring capabilities, positions the company favorably in meeting the evolving demands of both healthcare providers and patients seeking effective DBS solutions.

### **Key Companies in the Deep Brain Stimulators DBS Market Include**

- Jude Medical
- **[Medtronic](https://www.medtronic.com/en-us/healthcare-professionals/specialties/neurology/therapies-procedures/deep-brain-stimulation.html)**
- Braun Melsungen
- Abbott Laboratories
- Sientra
- NeuroPace
- Newron Pharmaceuticals
- Nervgen Pharma
- Medytox
- IntraCellular Therapies
- CereVel Therapeutics
- Electra Therapeutics
- Cala Health
- Boston Scientific
- Zimmer Biomet

### Deep Brain Stimulators Industry Developments

- **Q2 2024: FDA Approves Medtronic’s Percept™ RC Rechargeable Deep Brain Stimulation System** Medtronic announced FDA approval for its Percept™ RC, a rechargeable deep brain stimulation system designed to treat symptoms of Parkinson’s disease, essential tremor, and dystonia. The device features BrainSense™ technology, allowing clinicians to capture and record brain signals while delivering therapy.
- **Q1 2024: Boston Scientific Launches Vercise Genus™ Deep Brain Stimulation System in the U.S.** Boston Scientific announced the U.S. launch of its Vercise Genus™ DBS System, which offers expanded MRI compatibility and enhanced programming options for patients with Parkinson’s disease and other movement disorders.
- **Q2 2024: Abbott Receives CE Mark for Infinity™ Deep Brain Stimulation System with Directional Leads** Abbott received CE Mark approval for its Infinity™ DBS system with directional leads, enabling more precise targeting of brain regions for patients in Europe with Parkinson’s disease and essential tremor.
- **Q1 2024: NeuroPace Announces $67 Million Series F Funding to Advance Neuromodulation Therapies** NeuroPace raised $67 million in a Series F funding round to accelerate development and commercialization of its neuromodulation devices, including next-generation deep brain stimulation systems.
- **Q2 2024: Medtronic Opens New Manufacturing Facility for Neuromodulation Devices in Singapore** Medtronic inaugurated a new manufacturing facility in Singapore dedicated to producing deep brain stimulation and other neuromodulation devices, aiming to meet growing global demand.
- **Q3 2024: Aleva Neurotherapeutics Secures $35 Million in Funding to Expand Deep Brain Stimulation Portfolio** Aleva Neurotherapeutics closed a $35 million funding round to support the development and commercialization of its next-generation directional deep brain stimulation systems.
- **Q2 2024: Newronika Receives FDA Breakthrough Device Designation for AlphaDBS System** Newronika announced that its AlphaDBS system, a closed-loop deep brain stimulation device, received FDA Breakthrough Device Designation, expediting its path to market for Parkinson’s disease treatment.
- **Q1 2024: Abbott Appoints New Vice President of Neuromodulation Division** Abbott named Dr. Lisa Porter as Vice President of its Neuromodulation Division, overseeing the company’s deep brain stimulation and neuromodulation business strategy.
- **Q2 2024: Medtronic Announces Strategic Partnership with Brainlab for Advanced DBS Programming** Medtronic entered a strategic partnership with Brainlab to integrate advanced imaging and programming software into its deep brain stimulation systems, aiming to improve patient outcomes.
- **Q3 2024: Boston Scientific Receives FDA Approval for Expanded Indications of Vercise Genus™ DBS System** Boston Scientific received FDA approval to expand the indications of its Vercise Genus™ DBS System to include additional movement disorders beyond Parkinson’s disease.
- **Q2 2024: Aleva Neurotherapeutics Announces Partnership with Medtronic for Directional DBS Technology** Aleva Neurotherapeutics entered a partnership with Medtronic to co-develop and commercialize advanced directional deep brain stimulation technology for neurological disorders.
- **Q1 2024: NeuroPace Files for IPO to Fund Expansion of Neuromodulation Product Line** NeuroPace filed for an initial public offering (IPO) to raise capital for expanding its neuromodulation and deep brain stimulation product portfolio.

### **Deep Brain Stimulators DBS Market Segmentation Insights**

### **Deep Brain Stimulators DBS Market Device Type Outlook**

- Single Lead DBS
- Dual Lead DBS
- Adaptive DBS

### **Deep Brain Stimulators DBS Market Application Area Outlook**

- [Parkinson's Disease](../../../reports/parkinsons-disease-therapeutics-market-1572)
- Essential Tremor
- Dystonia
- Obsessive-Compulsive Disorder

### **Deep Brain Stimulators DBS Market Implantation Technique Outlook**

- Stereotactic Surgery
- Microelectrode Recording
- Neuroimaging Guided

### **Deep Brain Stimulators DBS Market End User Outlook**

- Hospitals
- Neurology Clinics
- Research Institutes

### **Deep Brain Stimulators DBS Market Technology Outlook**

- Conventional DBS Systems
- Closed-Loop DBS Systems
- Wireless DBS Systems

### **Deep Brain Stimulators DBS Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### 神经科学研究投资增加

对神经科学研究的投资激增是深脑刺激器（DBS）市场的重要驱动力。各国政府和私人组织越来越多地资助旨在理解神经系统疾病和开发创新治疗方式的研究项目。这一资金的涌入促进了对深脑刺激新应用的探索，可能将其使用范围扩展到传统适应症之外。例如，正在进行的研究正在调查DBS在治疗抑郁症和强迫症等疾病方面的疗效。随着研究不断揭示DBS的治疗潜力，深脑刺激器（DBS）市场可能会经历加速增长，新的临床应用和扩展的市场机会将推动这一增长。

### 深脑刺激设备中的技术创新

深脑刺激设备的技术进步正在显著影响深脑刺激器（DBS）市场。诸如闭环系统等创新，能够根据来自大脑的实时反馈调整刺激，从而提高治疗的有效性和安全性。此外，更小、更高效设备的推出使得手术侵入性降低，患者舒适度提高。预计DBS设备市场在未来五年内将见证约8%的年复合增长率，这一增长受到这些技术创新的推动。随着制造商继续投资于研发，深脑刺激器（DBS）市场有望实现显著增长，为神经系统疾病患者提供新的解决方案。

### 老龄化人口与医疗支出增加

老龄化人口是推动深脑刺激器（DBS）市场的关键因素。随着人们年龄的增长，发展神经系统疾病的可能性增加，从而导致对有效治疗方案的需求上升。此外，特别是在发达地区，医疗支出的增加正在促进对先进医疗技术的获取，包括深脑刺激器。报告显示，医疗支出预计将以每年5%的速度增长，为DBS疗法的采用创造了有利环境。老龄化人口与医疗投资增加的结合，可能会促进深脑刺激器（DBS）市场的发展，因为越来越多的患者寻求创新解决方案来管理他们的神经系统疾病。

### 神经系统疾病的发病率不断增加

神经系统疾病（如帕金森病、特发性震颤和肌张力障碍）发病率的上升是深脑刺激器（DBS）市场的主要驱动力。随着人口老龄化，这些疾病的患病率预计将上升，从而导致对有效治疗方案的需求增加。根据最近的估计，到2030年，帕金森病的诊断人数预计将达到120万人。不断增长的患者群体需要创新解决方案，包括深脑刺激，这在缓解症状方面显示出良好的效果。因此，神经系统疾病的患病率不断上升，可能会推动深脑刺激器（DBS）市场的增长，因为医疗服务提供者寻求先进的疗法以改善患者的治疗效果。

### 对深脑刺激疗法的认识和接受度不断提高

患者和医疗专业人员对深脑刺激疗法的日益关注和接受对深脑刺激器（DBS）市场至关重要。患者组织的教育倡议和宣传有助于更好地理解与DBS疗法相关的益处和风险。随着越来越多的患者了解他们的治疗选择，DBS手术的需求可能会增加。调查显示，近70%的神经科医生现在推荐DBS作为合格患者的可行治疗选择。这种观念的转变预计将推动深脑刺激器（DBS）市场的增长，因为越来越多的人寻求这种先进的治疗方法。

## Future Outlook

深脑刺激器（DBS）市场预计将在2024年至2035年间以5.89%的年均增长率增长，推动因素包括技术进步、神经系统疾病的日益普遍以及医疗支出的增加。

**New opportunities:**

- 开发下一代具有增强电池寿命和无线功能的DBS设备。 以量身定制的定价策略进入新兴市场，以提高可负担性。 与远程医疗平台建立合作伙伴关系，整合患者的远程监测解决方案。

到2035年，深脑刺激器（DBS）市场预计将实现显著增长和创新。

## Segment Insights

### 按设备类型：双导线DBS（最大）与自适应DBS（增长最快）

深脑刺激器（DBS）市场在其设备类型中表现出多样化的分布，特别是单导 DBS、双导 DBS 和自适应 DBS。双导 DBS 占据了最大的市场份额，主要由于其成熟的技术和在治疗运动障碍中的广泛应用。相比之下，单导 DBS 尽管有效，但随着越来越多的医疗服务提供者认识到双导系统的优势，逐渐被 overshadow。自适应 DBS 尽管目前在市场上的存在较小，但随着创新解决方案在临床环境中变得越来越普遍，显示出良好的增长潜力。

双导体深脑刺激（主导）与自适应深脑刺激（新兴）

双导DBS因其能够提供双侧刺激而被认为是深脑刺激器市场的主导者，增强了对神经系统疾病患者的治疗效果。其坚固的设计因治疗复杂病症如帕金森病和本质性震颤而受到赞誉。另一方面，自适应DBS代表了一种新兴趋势，其特点是具有先进的反馈机制，能够根据神经活动实时调整刺激。这种动态方法为患者提供了潜在的好处，通过根据他们特定的神经反应调整治疗，使其成为DBS技术未来发展的有希望的方向。

### 按应用领域：帕金森病（最大）与特发性震颤（增长最快）

在深脑刺激器（DBS）市场中，帕金森病占据了最大的份额，主导了应用领域细分，主要是由于这一神经系统疾病在老年人群体中的高发病率。特发性震颤是增长最快的细分市场，受益于对治疗选择的日益关注和设备技术的进步。这些细分市场共同展示了市场内的动态格局，反映了对针对性治疗干预的迫切需求。

帕金森病（显性）与本质性震颤（新兴）

帕金森病仍然是深脑刺激器（DBS）市场的主要应用，因为其已建立的治疗方案和强有力的临床证据支持刺激疗法。帕金森病患者通常需要长期治疗，导致对DBS设备的持续需求。另一方面，特发性震颤正迅速成为创新的焦点，受到技术进步的推动，这些进步提高了设备的疗效和患者的治疗效果。随着非侵入性和较少干扰的治疗选项的发展，特发性震颤的市场细分有望实现显著增长，代表着寻求有效管理解决方案的年轻患者人群。

### 通过植入技术：立体定向手术（最大）与微电极记录（增长最快）

在深脑刺激器（DBS）市场中，市场份额分布显示立体定向手术是最大的细分市场，占据了整体市场的显著部分。其在植入手术中精确定位的既定使用巩固了其在行业中的主导地位。另一方面，微电极记录也因其在实时神经元活动监测中的有效性而获得了显著的关注，迅速在从业者中开辟了一个日益受到认可的细分市场。

立体定向手术（主流）与微电极记录（新兴）

立体定向手术因其在靶向特定脑区的可靠性和精确性而成为深脑刺激市场的主导植入技术。这种成熟的方法使用三维坐标系统来定位电极放置区域，确保最佳结果。相反，微电极记录被视为一种新兴技术，通过允许在手术过程中实时记录神经信号，增强了传统方法的能力。这项技术显著改善了患者的治疗效果，并减少了术后并发症，使其在寻求先进解决方案的神经外科医生中越来越受欢迎。

### 按最终用户：医院（最大）与神经科诊所（增长最快）

在深脑刺激器（DBS）市场中，医院在终端用户领域占据了重要份额，这主要得益于它们提供全面护理和先进外科设施的能力。这些机构在实施DBS程序方面至关重要，广泛促进了积极的患者结果和持续的市场增长。尽管神经科诊所的市场份额相较于医院较小，但随着它们在管理神经系统疾病方面越来越被认可为专业治疗选择和创新方法，正在经历快速增长。

医院（主导）与神经科诊所（新兴）

医院仍然是深脑刺激器（DBS）市场的主要终端用户，具有丰富的资源、多学科团队以及进行复杂手术的能力。它们的良好声誉和现有的患者基础促进了DBS手术的稳定流动。相比之下，神经科诊所则呈现出一种新兴的替代选择，专注于量身定制的患者护理和可及性。这些专业中心正在获得关注，因为它们采用先进的技术和方法，使其能够吸引越来越多寻求DBS治疗帕金森病等疾病的患者，从而推动其在市场上的快速扩张。

### 按技术：传统DBS系统（最大）与闭环DBS系统（增长最快）

在深脑刺激器（DBS）市场中，传统DBS系统占据了最大的市场份额，反映了它们在临床环境中的长期存在和接受度。这些系统为各种神经系统疾病的患者提供了可靠的性能。然而，闭环DBS系统正在迅速崛起，由于其适应能力和与传统系统相比改善的患者结果而获得关注。它们能够实时自动调整刺激水平，吸引了医疗服务提供者和患者的极大关注。闭环DBS系统的增长受到传感器集成和算法开发技术进步的推动，这增强了它们的有效性。此外，研发投资的增加以及神经系统疾病的日益普遍，推动了对创新解决方案的需求。随着市场的发展，这些系统预计将在提供个性化治疗方面发挥关键作用，最终改善症状管理，提高患者的生活质量。

技术：传统深脑刺激系统（主导）与闭环深脑刺激系统（新兴）

传统的深脑刺激（DBS）系统长期以来一直是深脑刺激治疗的支柱，为帕金森病和特发性震颤等疾病提供了一致且有据可查的结果。它们的有效性已巩固了它们在临床实践中的地位，使其成为医生和患者的主流选择。然而，闭环DBS系统的引入标志着市场格局的重大转变。这些系统利用实时反馈回路，根据患者的生理信号自动调整刺激参数，代表了一种更个性化的治疗方法。因此，它们有望成为DBS市场的新兴力量，解决传统系统的局限性，并与日益增长的以患者为中心的护理需求相一致。

## Regional Market Share Analysis

全球深脑刺激器（DBS）市场在各个区域市场中有显著增长的潜力，展现出多样的动态和潜力。2023年，北美以21亿美元的市场估值领先，主要受益于先进的医疗基础设施和高发病率的神经系统疾病，确立了其主导地位。欧洲紧随其后，估值为15亿美元，反映出对医疗创新的投资不断增加以及DBS技术的采用日益普及。

亚太地区的估值为9亿美元，由于意识的提高和医疗设施的改善，展现出显著的机会，表明市场扩展的前景乐观。同时，南美和中东及非洲在2023年的市场份额较小，分别为1.8亿美元和1亿美元，但随着医疗服务的可及性和神经健康意识的提高，逐渐看到增长。收入分配显示北美和欧洲占据了绝大多数，突显了它们在全球深脑刺激器（DBS）市场行业中的关键角色，而亚太地区的增长潜力则反映了不断演变的医疗需求和市场需求。

**来源：初步研究、二次研究、MRFR数据库和分析师评审**

## Competitive Benchmarking

全球深脑刺激器（DBS）市场经历了显著增长，这得益于神经治疗技术的进步和运动障碍的日益普遍。该市场的竞争动态由创新、监管发展和主要参与者之间的战略合作共同塑造。各公司正专注于通过尖端功能和改进的安全性来增强其产品线。

市场格局的特点是越来越强调以患者为中心的护理，导致开发出优先考虑易用性和患者舒适度的DBS设备。随着新进入者的不断涌现，成熟公司正在利用其丰富的经验和临床数据来维持其市场地位，同时扩大其全球影响力。

圣犹达医疗公司在全球深脑刺激器DBS市场中占据了显著的地位，凭借其强大的创新产品组合，旨在治疗神经疾病。该公司因其对研究和开发的承诺而受到认可，使其能够通过提供先进的刺激技术来改善患者的治疗效果，从而在竞争中保持领先。圣犹达医疗公司专注于用户友好的设计和可定制的治疗方案，赢得了医疗专业人员和患者的信任。

该公司的战略合作伙伴关系和协作增强了其市场杠杆，而其强大的供应链和良好的客户关系表明其在满足全球各市场需求方面的竞争优势。强调临床证据以支持其产品进一步丰富了圣犹达医疗公司作为DBS领域可靠供应商的声誉。美敦力公司通过其对创新的承诺和全面的神经治疗方法，已在全球深脑刺激器DBS市场中确立了强大的竞争地位。

该公司因其在开发先进DBS系统方面的开创性工作而闻名，这些系统提供灵活的编程选项和精确的靶向功能，能够根据个体患者的需求量身定制治疗方案。

美敦力公司在[医疗设备](/zh-cn/reports/medical-devices-market-2869)领域的丰富经验增强了其信誉和市场地位，因为其产品得到了广泛的临床验证和安全数据的支持。强大的全球分销网络使美敦力能够有效地接触到多样化的患者群体。此外，美敦力致力于整合先进技术，如软件进步和远程监控能力，使其在满足医疗提供者和寻求有效DBS解决方案的患者不断变化的需求方面处于有利地位。

## Recent News & Developments

- **2024年第二季度：FDA批准美敦力的Percept™ RC可充电深脑刺激系统** 美敦力宣布获得FDA批准，其Percept™ RC是一种可充电的深脑刺激系统，旨在治疗帕金森病、特发性震颤和肌张力障碍的症状。该设备具有BrainSense™技术，允许临床医生在提供治疗的同时捕捉和记录脑信号。
- **2024年第一季度：波士顿科学在美国推出Vercise Genus™深脑刺激系统** 波士顿科学宣布在美国推出其Vercise Genus™ DBS系统，该系统为帕金森病和其他运动障碍患者提供了扩展的MRI兼容性和增强的编程选项。
- **2024年第二季度：雅培获得Infinity™深脑刺激系统的CE标志，配备定向导线** 雅培获得了其Infinity™ DBS系统的CE标志批准，该系统配备定向导线，使欧洲的帕金森病和特发性震颤患者能够更精确地定位脑区。
- **2024年第一季度：NeuroPace宣布获得6700万美元的F轮融资，以推进神经调节疗法** NeuroPace在F轮融资中筹集了6700万美元，以加速其神经调节设备的开发和商业化，包括下一代深脑刺激系统。
- **2024年第二季度：美敦力在新加坡开设新的神经调节设备制造工厂** 美敦力在新加坡启用了一个新的制造工厂，专注于生产深脑刺激和其他神经调节设备，旨在满足日益增长的全球需求。
- **2024年第三季度：Aleva Neurotherapeutics获得3500万美元融资，以扩展深脑刺激产品组合** Aleva Neurotherapeutics完成了一轮3500万美元的融资，以支持其下一代定向深脑刺激系统的开发和商业化。
- **2024年第二季度：Newronika获得FDA突破性设备认证，针对AlphaDBS系统** Newronika宣布其AlphaDBS系统，一种闭环深脑刺激设备，获得FDA突破性设备认证，加快其在帕金森病治疗市场的进程。
- **2024年第一季度：雅培任命新的神经调节部门副总裁** 雅培任命Dr. Lisa Porter为其神经调节部门副总裁，负责公司的深脑刺激和神经调节业务战略。
- **2024年第二季度：美敦力宣布与Brainlab建立战略合作伙伴关系，以实现先进的DBS编程** 美敦力与Brainlab建立战略合作伙伴关系，将先进的成像和编程软件整合到其深脑刺激系统中，旨在改善患者的治疗效果。
- **2024年第三季度：波士顿科学获得FDA批准，扩展Vercise Genus™ DBS系统的适应症** 波士顿科学获得FDA批准，扩展其Vercise Genus™ DBS系统的适应症，以包括帕金森病以外的其他运动障碍。
- **2024年第二季度：Aleva Neurotherapeutics宣布与美敦力合作开发定向DBS技术** Aleva Neurotherapeutics与美敦力达成合作，共同开发和商业化针对神经系统疾病的先进定向深脑刺激技术。
- **2024年第一季度：NeuroPace申请首次公开募股，以资助神经调节产品线的扩展** NeuroPace申请首次公开募股（IPO），以筹集资金扩展其神经调节和深脑刺激产品组合。

## Report Scope

| 2024年市场规模 | 5.355（十亿美元） |
| --- | --- |
| 2025年市场规模 | 5.671（十亿美元） |
| 2035年市场规模 | 10.05（十亿美元） |
| 年复合增长率（CAGR） | 5.89%（2024 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 十亿美元 |
| 主要公司简介 | 市场分析进行中 |
| 覆盖的细分市场 | 市场细分分析进行中 |
| 主要市场机会 | 神经技术的进步增强了深脑刺激器市场的治疗选择。 |
| 主要市场动态 | 技术进步和监管变化推动深脑刺激器市场的创新和竞争。 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 截至2024年，深脑刺激器（DBS）市场的当前估值是多少？**
A: 2024年市场估值为53.55亿美元。

**Q: 2035年深脑刺激器（DBS）市场的预计市场规模是多少？**
A: 2035年的预计估值为100.5亿美元。

**Q: 在2025年至2035年的预测期内，深脑刺激器（DBS）市场的预期复合年增长率（CAGR）是多少？**
A: 在此期间，预期的CAGR为5.89%。

**Q: 在深脑刺激器（DBS）市场中，哪些公司被视为关键参与者？**
A: 主要参与者包括美敦力、波士顿科学、雅培、神经节律、圣犹达医疗、史赛克、Zynex 和 Bioness。

**Q: 深脑刺激器DBS市场中有哪些不同的设备类型？**
A: 设备类型包括单导 DBS、双导 DBS 和自适应 DBS。

**Q: 2025年单一引导DBS的市场估值是多少？**
A: 单导线DBS的市场估值预计将在15亿到30亿美元之间。

**Q: 2025年，帕金森病市场与其他应用领域相比如何？**
A: 帕金森病市场预计在25亿到45亿美元之间，领先其他应用领域。

**Q: 在深脑刺激器（DBS）市场中使用了哪些植入技术？**
A: 植入技术包括立体定向手术、微电极记录和神经影像引导。

**Q: 到2025年，医院作为最终用户的预期市场规模是多少？**
A: 预计医院作为最终用户的市场规模将在25亿至45亿美元之间。

**Q: 在深脑刺激器（DBS）市场中正在开发哪些技术？**
A: 技术包括传统DBS系统、闭环DBS系统和无线DBS系统。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/deep-brain-stimulators-market-32343*